IFNG and neoplasm: Moreover, tumours derived from cells chronically treated with IFNγ prior to implantation in syngeneic mice are resistant to ICBT9; while in vivo CRISPR screens revealed IFNγ signalling as a driver of ICBT resistance in multiple syngeneic mouse tumour implantation models10.